Aquestive Therapeutics In...
3.04
-0.07 (-2.25%)
At close: Jan 14, 2025, 3:59 PM
3.06
0.49%
After-hours Jan 14, 2025, 04:07 PM EST
undefined%
Bid 3.02
Market Cap 277.64M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.46
PE Ratio (ttm) -6.62
Forward PE n/a
Analyst Buy
Ask 3.06
Volume 1,019,935
Avg. Volume (20D) 1,596,690
Open 3.14
Previous Close 3.11
Day's Range 3.01 - 3.27
52-Week Range 2.24 - 6.23
Beta undefined

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...

Sector Healthcare
IPO Date Jul 25, 2018
Employees 135
Stock Exchange NASDAQ
Ticker Symbol AQST

Analyst Forecast

According to 8 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 195.57% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Aquestive Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $13.13M, reflecting a -0.58% YoY shrinking and earnings per share of -0.13, making a 30.00% increase YoY.
3 weeks ago · Source
+5.2%
Aquestive Therapeutics shares are trading higher a... Unlock content with Pro Subscription
4 weeks ago · Source
+6.94%
Aquestive Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $17.